Cargando…

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma

Detalles Bibliográficos
Autores principales:	Stover, Elizabeth H., Feltmate, Colleen, Berkowitz, Ross S., Lindeman, Neal I., Matulonis, Ursula A., Konstantinopoulos, Panagiotis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394870/ https://www.ncbi.nlm.nih.gov/pubmed/30828692 http://dx.doi.org/10.1200/PO.18.00135

Ejemplares similares

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report
por: Silva, R., et al.
Publicado: (2022)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
por: Strickland, Kyle C., et al.
Publicado: (2016)

Detection of ESR1 Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients
por: Stergiopoulou, Dimitra, et al.
Publicado: (2022)

Osseous Metaplasia in Low-grade Ovarian Serous Carcinoma With a BRAF Mutation: A Case Report
por: Catteau, Xavier, et al.
Publicado: (2021)

KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions
por: Nakamura, Kohei, et al.
Publicado: (2016)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
por: Yu, Kun-Hsing, et al.
Publicado: (2020)

High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary
por: Matulonis, Ursula A., et al.
Publicado: (2011)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Robotic single-site excision of ovarian endometrioma
por: Gargiulo, Antonio R., et al.
Publicado: (2015)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
por: Chui, M. Herman, et al.
Publicado: (2019)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary
por: Xu, Yan, et al.
Publicado: (2017)

Correction: BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
por: Chui, M. Herman, et al.
Publicado: (2021)

Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
por: Neal, Adam, et al.
Publicado: (2021)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
por: Launonen, I.-M., et al.
Publicado: (2022)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
por: Lima, Bárbara, et al.
Publicado: (2022)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
por: D’Ambrosio, Concetta, et al.
Publicado: (2020)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dg352s40gmk2hljbhadn3fsdq7